Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies
Enveric Biosciences Highlights Results for EB-003 In PTSD Preclinical Model; Says Previously Reported Results Support Continued Development Of EB-003 For PTSD, Other Neuropsychiatric Condition
Enveric Biosciences shares are trading higher after the FDA announced accelerated efforts to advance treatments for serious mental illnesses, following an executive order signed by President Trump.
Enveric Bioscience Shares Resume Trade
Enveric Biosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 34.58%
Enveric Biosciences Files Prospectus Related To Resale Of Up To 6.82M Shares Of Common Stock
Enveric Biosciences Canada Granted U.S. Patent Over Carboxylated Psilocybin Derivatives And Methods Of Using
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
Enveric Biosciences shares are trading higher after President Trump signed an executive order on accelerating medical treatments for serious mental illness.
Enveric Biosciences shares are trading lower after the company announced a $13.9 million private placement of 2,222,223 shares at $2.25 per share and accompanying warrant.
Reported Earlier, Enveric Biosciences Prices At-The-Market Private Placement Of 2.2M Shares At $2.25, Raising Up To $13.9M With Warrants
Enveric Biosciences Receives U.S. Patent For Its EVM301 Series Of Molecules
Enveric Biosciences Q4 EPS $(0.50) Up From $(57.96) YoY
Enveric Biosciences Announces Five Trademark Registrations With Canadian Intellectual Property Office
Enveric Biosciences shares are trading higher after the company announced Post-Grant Review petition filed by Gilgamesh against Enveric's patent has been withdrawn.
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.